Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beyond Air, Inc.XAIR · Entity 8379 | Director | November 22, 2024 | November 27, 2024 |
| Nuvectis Pharma, Inc.NVCT · Entity 5166 | Director · Chairman & CEO · 10% owner | June 30, 2026 | July 01, 2026 |
| UroGen Pharma Ltd.URGN · Entity 4466 | Director · Chief Executive Officer | January 01, 2019 | January 10, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beyond Air, Inc.
Report date November 22, 2024 · Filed November 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 | Direct | 0 |
Reported balance
After 2024-11-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-11-22 · Disposition to issuer · Disposed 45,000 · Balance 0 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 45,000 |
Reported balance
After 2024-11-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-11-22 · Grant · Acquired 45,000 · Balance 45,000 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.28 | Direct | 0 |
Reported balance
After 2024-11-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-11-22 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 40,000 |
Reported balance
After 2024-11-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-11-22 · Grant · Acquired 40,000 · Balance 40,000 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.87 | Direct | 0 |
Reported balance
After 2024-11-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-11-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 30,000 |
Reported balance
After 2024-11-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-11-22 · Grant · Acquired 30,000 · Balance 30,000 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.45 | Direct | 0 |
Reported balance
After 2024-11-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-11-22 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 25,000 |
Reported balance
After 2024-11-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-11-22 · Grant · Acquired 25,000 · Balance 25,000 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.32 | Direct | 0 |
Reported balance
After 2024-11-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-11-22 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 25,000 |
Reported balance
After 2024-11-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-11-22 · Grant · Acquired 25,000 · Balance 25,000 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 | Direct | 0 |
Reported balance
After 2024-11-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-11-22 · Disposition to issuer · Disposed 24,000 · Balance 0 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 24,000 |
Reported balance
After 2024-11-22 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-11-22 · Grant · Acquired 24,000 · Balance 24,000 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged.
F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Nuvectis Pharma, Inc.
Report date June 30, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,688,424 |
Reported balance
After 2026-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-30 · Purchase · Acquired 12,500 · Balance 3,688,424 F1: Mr. Bentsur purchased 12,500 shares for $250,000 in the public offering announced on June 29, 2026. F2: Includes shares of restricted common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Bentsur purchased 12,500 shares for $250,000 in the public offering announced on June 29, 2026.
F2: Includes shares of restricted common stock.
UroGen Pharma Ltd.
Report date January 01, 2019 · Filed January 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 38,113 |
Reported balance
Holding disclosure · report date 2019-01-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 38,113 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F1: 25% of the restricted stock units ("RSUs") vested on August 9, 2016 and 2.778% of the remaining RSUs will vest in equal monthly installments thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.55 · Expires 2027-06-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: 8.33% of the shares underlying the stock option will vest in equal quarterly installments commencing 3 months after June 28, 2017. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.67 · Expires 2028-01-10 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: 2.778% of the shares underlying the stock option will vest in equal monthly installments commencing 1 month after January 10, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the restricted stock units ("RSUs") vested on August 9, 2016 and 2.778% of the remaining RSUs will vest in equal monthly installments thereafter.
F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F3: 8.33% of the shares underlying the stock option will vest in equal quarterly installments commencing 3 months after June 28, 2017.
F4: 2.778% of the shares underlying the stock option will vest in equal monthly installments commencing 1 month after January 10, 2018.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
STEMLINE THERAPEUTICS INC
Report date June 10, 2020 · Filed June 10, 2020
Section 16 reporting ended · disclosed 2020-06-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 1
1 source rowRow 1 · 2020-06-10 · Other · Disposed 66,346 · Balance 0 F1: Disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020 (the "Merger Agreement"), in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share (collectively, the "Offer Price"). Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.92 · Expires 2021-03-08 | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-10 · Disposition to issuer · Disposed 9,034 · Balance 0 F3: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2: All options were vested and exercisable as of the effective time of the merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2022-03-09 | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-10 · Disposition to issuer · Disposed 18,070 · Balance 0 F3: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2: All options were vested and exercisable as of the effective time of the merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.78 · Expires 2026-05-25 | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-06-10 · Disposition to issuer · Disposed 34,000 · Balance 0 F3: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2: All options were vested and exercisable as of the effective time of the merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.20 · Expires 2027-06-19 | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-06-10 · Disposition to issuer · Disposed 24,000 · Balance 0 F3: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2: All options were vested and exercisable as of the effective time of the merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020 (the "Merger Agreement"), in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share (collectively, the "Offer Price"). Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021.
F2: All options were vested and exercisable as of the effective time of the merger.
F3: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 22, 2021 Filed Nov 24, 2021 21:15 UTC | Beyond Air, Inc. XAIR · Entity 8379 | Tax withholdingCommon Stock | 12,536 | $14.60 | $182,987.99 |
DisclosureSEC source: 0001493152-21-029833 · ownership.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,900 F1 · kind: On November 22, 2021, shares of common stock, par value $0.0001 per share, of Beyond Air, Inc. (the "Company") were issued to the reporting person in connection with the exercise of a warrant to purchase 50,000 shares of common stock of the Company for $3.66 a share. The reporting person paid the exercise price on a cashless basis, resulting in the Company's withholding of 12,536 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 37,464 shares of common stock of the Company. These transactions were exempt from Section 16(b) of the Securities Exchange Act of 1934 pursuant to Rule 16b-3. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 21:15 UTC | Beyond Air, Inc. XAIR · Entity 8379 | Exercise / conversionCommon Stock | 50,000 | $3.66 | $183,000.00 |
DisclosureSEC source: 0001493152-21-029833 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 00:53 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001493152-21-005621 · ownership.xml · derivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · Not disclosed shares Expires 2031-03-03 F1 · derivative.exercise_date: The option will vest as to 25% of the shares of common stock underlying the option on December 31, 2021, with the remainder vesting in equal annual installments on December 31 of each of the three ensuing years thereafter until vested in full. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 21:14 UTC | Beyond Air, Inc. XAIR · Entity 8379 | Exercise / conversionTranche B Warrant (Right to Buy) · Derivative | 23,419 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001493152-21-004261 · ownership.xml · derivative · entry 4 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,419 shares Expires 2021-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 21:14 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 23,419 | $6.36 | $148,944.84 |
DisclosureSEC source: 0001493152-21-004261 · ownership.xml · nonDerivative · entry 3 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,436 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.20 to $6.50, inclusive. The reporting person undertakes to provide to Beyond Air, Inc., any security holder of Beyond Air, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 21:14 UTC | Beyond Air, Inc. XAIR · Entity 8379 | Exercise / conversionCommon Stock | 23,419 | $4.25 | $99,530.75 |
DisclosureSEC source: 0001493152-21-004261 · ownership.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2021 Filed Feb 18, 2021 21:14 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 1,500 | $6.28 | $9,420.00 |
DisclosureSEC source: 0001493152-21-004261 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,436 F1 · acquired: The sale was made to satisfy certain Israeli tax obligations. Read SEC document |
| January 02, 2021 Filed Feb 9, 2021 01:08 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 5,700 | $5.89 | $33,573.00 |
DisclosureSEC source: 0001493152-21-003005 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,936 F1 · acquired: The sale was made to satisfy certain Israeli tax obligations. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 21:40 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 1,580 | $5.95 | $9,406.21 |
DisclosureSEC source: 0001493152-20-016856 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,636 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices with a highest price of $6.06 and a lowest price of $5.76. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 01:00 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 3,889 | $5.68 | $22,104.30 |
DisclosureSEC source: 0001493152-20-016710 · ownership.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,216 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices with a $1.00 range. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| August 21, 2020 Filed Aug 26, 2020 01:00 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 3,246 | $6.05 | $19,650.63 |
DisclosureSEC source: 0001493152-20-016710 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,105 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices with a $1.00 range. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 21:00 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 3,778 | $6.29 | $23,779.87 |
DisclosureSEC source: 0001493152-20-016525 · ownership.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,351 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 21:00 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 6,533 | $6.32 | $41,265.69 |
DisclosureSEC source: 0001493152-20-016525 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,129 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 21:00 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 4,578 | $5.83 | $26,691.11 |
DisclosureSEC source: 0001493152-20-016331 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,662 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 21:00 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 4,413 | $5.72 | $25,226.03 |
DisclosureSEC source: 0001493152-20-016211 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,240 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 14, 2020 Filed Aug 17, 2020 22:51 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 6,680 | $5.53 | $36,931.72 |
DisclosureSEC source: 0001493152-20-016122 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,653 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 21:40 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 4,088 | $5.50 | $22,494.22 |
DisclosureSEC source: 0001493152-20-015976 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,333 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 12, 2020 Filed Aug 13, 2020 20:30 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 4,689 | $5.30 | $24,834.35 |
DisclosureSEC source: 0001493152-20-015547 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,421 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 00:24 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 3,910 | $5.51 | $21,552.70 |
DisclosureSEC source: 0001493152-20-015399 · ownership.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,110 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 10, 2020 Filed Aug 13, 2020 00:24 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 3,437 | $5.42 | $18,635.76 |
DisclosureSEC source: 0001493152-20-015399 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,020 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 22:06 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 10,222 | $5.35 | $54,657.03 |
DisclosureSEC source: 0001493152-20-015135 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,374 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 06, 2020 Filed Aug 8, 2020 00:53 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 6,192 | $5.94 | $36,777.38 |
DisclosureSEC source: 0001493152-20-015015 · ownership.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,596 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 05, 2020 Filed Aug 8, 2020 00:53 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 3,619 | $6.16 | $22,286.16 |
DisclosureSEC source: 0001493152-20-015015 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,788 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 04, 2020 Filed Aug 6, 2020 21:00 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 3,649 | $6.13 | $22,369.46 |
DisclosureSEC source: 0001493152-20-014877 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,407 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 21:05 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 3,814 | $6.16 | $23,488.52 |
DisclosureSEC source: 0001493152-20-014601 · ownership.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,056 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 21:05 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 2,868 | $6.27 | $17,969.74 |
DisclosureSEC source: 0001493152-20-014601 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,870 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 30, 2020 Filed Jul 31, 2020 22:26 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 3,418 | $6.26 | $21,403.86 |
DisclosureSEC source: 0001493152-20-014402 · ownership.xml · nonDerivative · entry 3 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,738 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 22:26 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 1,827 | $6.09 | $11,135.20 |
DisclosureSEC source: 0001493152-20-014402 · ownership.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,156 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 22:26 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 2,516 | $6.20 | $15,596.18 |
DisclosureSEC source: 0001493152-20-014402 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,983 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 27, 2020 Filed Aug 13, 2020 00:19 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 4,917 | $6.27 | $30,806.97 |
DisclosureSEC source: 0001493152-20-015397 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,582 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 11:19 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | Disposition to issuerStock Option (right to buy) · Derivative | 24,000 | Not disclosed Strike: $8.20 | Not disclosed |
DisclosureSEC source: 0001104659-20-071836 · a4.xml · derivative · entry 5 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2027-06-19 F3 · price: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2 · derivative.exercise_date: All options were vested and exercisable as of the effective time of the merger. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 11:19 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | Disposition to issuerStock Option (right to buy) · Derivative | 34,000 | Not disclosed Strike: $6.78 | Not disclosed |
DisclosureSEC source: 0001104659-20-071836 · a4.xml · derivative · entry 4 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,000 shares Expires 2026-05-25 F3 · price: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2 · derivative.exercise_date: All options were vested and exercisable as of the effective time of the merger. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 11:19 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | Disposition to issuerStock Option (right to buy) · Derivative | 18,070 | Not disclosed Strike: $3.30 | Not disclosed |
DisclosureSEC source: 0001104659-20-071836 · a4.xml · derivative · entry 3 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,070 shares Expires 2022-03-09 F3 · price: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2 · derivative.exercise_date: All options were vested and exercisable as of the effective time of the merger. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 11:19 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | Disposition to issuerStock Option (right to buy) · Derivative | 9,034 | Not disclosed Strike: $2.92 | Not disclosed |
DisclosureSEC source: 0001104659-20-071836 · a4.xml · derivative · entry 2 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,034 shares Expires 2021-03-08 F3 · price: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2 · derivative.exercise_date: All options were vested and exercisable as of the effective time of the merger. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 11:19 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | OtherCommon Stock | 66,346 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-071836 · a4.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020 (the "Merger Agreement"), in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share (collectively, the "Offer Price"). Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021. Read SEC document |
| June 25, 2019 Filed Jun 28, 2019 17:14 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-038302 · a4.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,443 F3 · shares: The restricted shares will vest on 6/25/2020. F4 · balance_after: Of the 65,443 shares, 37,105 shares are restricted stock. Read SEC document |
| June 25, 2019 Filed Jun 28, 2019 17:14 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-038302 · a4.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,443 F1 · shares: The restricted shares will vest according to the following schedule: 5,000 shares on 6/25/2020, 5,000 shares on 6/25/2021 and 5,000 shares on 6/25/2022. F2 · balance_after: Of the 55,443 shares, 27,105 shares are restricted stock. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 21:30 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GrantCommon Stock | 13,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-041867 · a4.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,443 F1 · shares: The restricted shares will vest according to the following schedule: 4,386 shares on 6/21/2019, 4,386 shares on 6/21/2020 and 4,386 shares on 6/21/2021. F2 · balance_after: Of the 40,443 shares, 23,157 shares are restricted stock. Read SEC document |
| February 16, 2018 Filed May 15, 2018 20:28 UTC | Beyond Air, Inc. AITB · Entity 8379 | Exercise / conversionTranche A Warrant (right to buy) · Derivative | 23,419 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001178913-18-001672 · zk1821693.xml · derivative · entry 4 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 23,419 shares Expires 2018-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2018 Filed May 15, 2018 20:28 UTC | Beyond Air, Inc. AITB · Entity 8379 | PurchaseTranche B Warrant (right to buy) · Derivative | 23,419 | $0.01 Strike: $4.25 | $234.19 |
DisclosureSEC source: 0001178913-18-001672 · zk1821693.xml · derivative · entry 3 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,419 Underlying: Common stock · 23,419 shares Expires 2021-02-15 Read SEC document |
| February 16, 2018 Filed May 15, 2018 20:28 UTC | Beyond Air, Inc. AITB · Entity 8379 | PurchaseTranche A Warrant (right to buy) · Derivative | 23,419 | $0.01 Strike: $4.25 | $234.19 |
DisclosureSEC source: 0001178913-18-001672 · zk1821693.xml · derivative · entry 2 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,419 Underlying: Common stock · 23,419 shares Expires 2018-02-19 Read SEC document |
| February 16, 2018 Filed May 15, 2018 20:28 UTC | Beyond Air, Inc. AITB · Entity 8379 | Exercise / conversionCommon Stock | 23,419 | $4.25 | $99,530.75 |
DisclosureSEC source: 0001178913-18-001672 · zk1821693.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2017 Filed Jun 20, 2017 17:17 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GrantStock Options (right to buy) · Derivative | 24,000 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0001104659-17-040455 · a4.xml · derivative · entry 2 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2027-06-19 F3 · derivative.exercise_date: The options will vest according to the following schedule: one-third on each of 6/19/2018, 6/19/2019, and 6/19/2020. Read SEC document |
| June 19, 2017 Filed Jun 20, 2017 17:17 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-040455 · a4.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,285 F1 · shares: The restricted shares will vest according to the following schedule: 3,334 shares on 6/19/2018, 3,333 shares on 6/19/2019 and 3,333 shares on 6/19/2020. F2 · balance_after: Of the 27,285 shares, 16,666 shares are restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.